Oberland Capital Management closed its third fund centered on healthcare innovation, with $1.2 billion in investor commitments following six months of fundraising.
Oberland Capital Healthcare Fund III is a royalty and credit fund that offers attractive, non-dilutive sources of capital to leading biotechnology and pharmaceutical companies, research institutions and inventors, said Jean-Pierre Naegeli, managing partner at Oberland Capital in New York.
One of the fund’s investors was the Texas Municipal Retirement System, which placed $110 million in the main fund and another $55 million in co-investment structure.
“We greatly appreciate the strong support from both existing and new investors and their confidence in Oberland Capital’s specialized healthcare investment strategy focused on innovative therapeutics, diagnostics and medical devices that play an important role in the treatment paradigm for serious diseases,” said Oberland Managing Partner Andrew Rubinstein in a statement.
Naegeli and Rubenstein worked together at healthcare royalty firm Paul Capital before forming Oberland in 2013. Prior to working in investments Naegeli spent a decade at Johnson & Johnson and Rubenstein was the CEO of Microban International.
Oberland assets under management are now in excess of $3 billion.
Oberland Capital Management closed its third fund centered on healthcare innovation, with $1.2 billion in investor commitments following six months of fundraising.
Oberland Capital Healthcare Fund III is a royalty and credit fund that offers attractive, non-dilutive sources of capital to leading biotechnology and pharmaceutical companies, research institutions and inventors, said Jean-Pierre Naegeli, managing partner at Oberland Capital in New York.
On of the fund’s investors was the Texas Municipal Retirement System, which placed $110 million in the main fund and another $55 million in co-investment structure.
“We greatly appreciate the strong support from both existing and new investors and their confidence in Oberland Capital’s specialized healthcare investment strategy focused on innovative therapeutics, diagnostics and medical devices that play an important role in the treatment paradigm for serious diseases,” said Oberland Managing Partner Andrew Rubinstein in a statement.
Naegeli and Rubenstein worked together at healthcare royalty firm Paul Capital before forming Oberland in 2013. Prior to working in investments Naegeli spent a decade at Johnson & Johnson and Rubenstein was the CEO of Microban International.
Oberland assets under management are now in excess of $3 billion.
